Inpatient Management Techniques for Gastrointestinal & Liver Care

Delve into the complexities of inpatient management and its impact on improving health outcomes in liver and gastrointestinal function.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I walk you through practical, modern, evidence-based strategies for inpatient management of complex gastroenterology and hepatology problems. I present a clear, stepwise approach to triaging and treating upper and lower GI bleeding, optimizing anticoagulation decisions, and distinguishing cholangitis from choledocholithiasis. I also cover oropharyngeal versus esophageal dysphagia, severe ulcerative colitis and Crohn’s disease flares, acute pancreatitis care, and small bowel obstruction and fecal impaction strategies. On the hepatology side, I explain restrictive transfusion thresholds in cirrhosis; acute liver failure criteria and early N-acetylcysteine use; precipitating factors and treatments for hepatic encephalopathy; hepatorenal syndrome management; portal vein thrombosis; ascites management; and the difference between liver injury enzymes and liver function markers. Throughout, I show how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas integrates chiropractic care, functional medicine, rehabilitation, and internal medicine oversight to support whole-person recovery and reduce readmissions, highlighting clinical observations and the latest findings from leading researchers.

Our Multidisciplinary Model: Medical Oversight and Integrative Care

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, my practice operates in a collaborative, integrative model common to injury and functional care clinics. Dr. Maria Guadalupe Cardenas, MD — Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) — serves as our Medical Director and Collaborative Physician. With over 40 years of experience, Dr. Cardenas provides comprehensive medical direction, inpatient coordination, and evidence-based internal medicine guidance, while I direct integrative chiropractic and functional rehabilitation strategies. This structure allows an MD to provide medical oversight alongside a chiropractor, ensuring safety, coherence, and depth of care.

How We Integrate Care

• Medical oversight (Internal Medicine, Dr. Cardenas): Diagnostic workup, hospital-to-ambulatory transitions, medication management, anticoagulation decisions, and procedural coordination.
• Integrative chiropractic care (Dr. Jimenez): Mechanical assessment, regional interdependence modeling, spinal and extremity adjustments (as indicated), graded mobility, motor control retraining, and pain-modulating manual therapies.
• Functional medicine: Nutrition optimization, microbiome balance, endocrine/metabolic drivers, inflammatory load reduction, validated testing, and targeted supplementation.
• Rehabilitation: Dosage-specific exercise therapy for tissue capacity building; neuromuscular retraining; fascia and myofascial interventions; ergonomics and graded load management.
• Personal injury care: Documentation, causation analysis, functional restoration, coordinated imaging, and safe recovery pathways.

This integrated approach reduces modifiable risks (e.g., NSAID exposure), improves physiologic resilience (nutrition, activity), and aligns endoscopic, pharmacologic, and rehabilitative care so patients recover faster and more safely.

Upper GI Bleeding: Triage, Physiology, and Endoscopic Strategy

I begin by distinguishing urgent upper GI bleeding from cases that are safe for expedited outpatient evaluation. Melena often suggests a proximal source, yet slow colonic transit in older adults can present right-sided colonic bleeding as melena. Melena can persist up to five days after bleeding stops. I correlate stool appearance with hemodynamics, symptoms, and serial hemoglobin.

Red Flags for Urgent Upper Source

• Hemodynamic instability: presyncope/syncope, tachycardia, hypotension
• Ongoing hematemesis or maroon/bright red hematochezia suggesting brisk upper source
• Cirrhosis/portal hypertension, variceal risk
• Rising BUN/Cr ratio from digested blood nitrogen load (Laine & Jensen, 2012)

Common Etiologies

• Peptic ulcer disease, varices, portal hypertensive gastropathy
• Malignancy, marginal ulcers post-Roux-en-Y
• Mallory-Weiss tears
• Pill esophagitis (e.g., doxycycline)

Why This Matters Physiologically

• Blood digestion in the upper GI tract elevates BUN
• Portal hypertension increases variceal rupture risk; vasoconstrictors reduce portal inflow.
• NSAIDs inhibit COX, reducing mucosal prostaglandins and bicarbonate/mucus protection.

Immediate Management Priorities

• Resuscitation: IV fluids, crossmatch; airway protection if ongoing hematemesis.
• Pharmacologic hemostasis:

• High-dose IV PPI to stabilize clots on exposed vessels (Laine & Jensen, 2012).
• If varices suspected: octreotide infusion plus antibiotics to lower infection and rebleeding (Chavez-Tapia et al., 2013).

• Medication reconciliation: I explicitly name OTC NSAIDs and combinations: ibuprofen, naproxen, meloxicam, aspirin, BC powder, Alka-Seltzer. Patients often omit these unless specifically asked.

Endoscopy Timing and Risk Stratification

• Target EGD within 12–24 hours after stabilization for most admitted patients (Barkun et al., 2019).
• Use Glasgow-Blatchford Score to guide admission vs. outpatient pathways. Low-risk profiles with normal hemoglobin and stable vitals may be suitable for outpatient evaluation.

When melena persists, but vitals and hemoglobin are stable, I consider residual blood transit; with dizziness or presyncope, I assume ongoing bleeding and non-diagnostic GD; if anemia is severe, I expand to colonoscopy or CT angiography. For obscure bleeding, I consider CT angiography and push enteroscopy to reach distal duodenum and proximal jejunum.

Lower GI Bleeding: Timing, Pain Clues, and Strategy

In lower GI bleeding, I ask early: has this happened before, can the patient prep for colonoscopy, and could hematochezia reflect brisk upper bleeding? Evidence supports measured timing: urgent (<24h) vs. elective (24–96h) colonoscopy often shows no significant difference in key outcomes when prep is optimized; rushing a poorly prepared exam is non-diagnostic (Laine et al., 2019; Strate et al., 2019).

Pain Guides Differential

• Painless bleeding: diverticulosis, angiodysplasia, internal hemorrhoids
• Painful bleeding: ischemic colitis, IBD, infectious colitis, malignancy

I match findings to physiology: a tiny, non-bleeding gastric erosion does not explain a hemoglobin level of 4 g/dL; I escalate imaging and colonoscopy as appropriate.

Anticoagulation During GI Bleeding: Balancing Risks

I weigh the thrombotic risk of holding anticoagulation versus the rebleeding risk of continuing it. Decisions hinge on indication (e.g., mechanical valve, high-risk AF), severity, timing of last dose, renal function, and concomitant NSAIDs/aspirin.

Reversal and Resumption

• Warfarin: Vitamin K and 4-factor PCC for life-threatening bleeding (Tomaselli et al., 2017).
• DOACs: idarucizumab (dabigatran); andexanet alfa or PCC for factor Xa inhibitors, guided by onset and renal status.
• Restarting: For high-thrombotic-risk patients, I resume within 7 days after hemostasis, which reduces thromboembolic events and mortality while maintaining an acceptable rebleed risk (Qureshi et al., 2014).

In hospital, I sometimes use a heparin infusion bridge (short half-life) to test tolerance, enabling rapid reversal if rebleeding occurs.

Considering Alternatives

For AF patients with recurrent bleeding, I advocate discussing Watchman left atrial appendage closure as a pathway to reduce long-term anticoagulant dependence when appropriate.

Dysphagia: Oropharyngeal vs. Esophageal Pathways

I differentiate oropharyngeal dysphagia (difficulty initiating swallow, nasal regurgitation, coughing/choking) from esophageal dysphagia (food sticking sensation seconds after swallowing). Solids,s then liquids suggest mechanical stricture; liquids ± solids suggest motility disorder.

• Oropharyngeal evaluation: bedside swallow, modified barium swallow for aspiration risk.
• Esophageal workup: EGD for structural lesions, then manometry if needed (ASGE Standards of Practice Committee, 2014).

Mechanism guides care: oropharyngeal dysfunction demands swallow safety; esophageal pathology benefits from dilation, anti-reflux therapy, or motility-directed interventions.

IBD Flares: Steroids, Biologics, and Thromboprophylaxis

For severe ulcerative colitis, I start IV corticosteroids (e.g., methylprednisolone 60 mg/day). Non-response within 3–5 days triggers rescue therapy (infliximab or cyclosporine) (Rubin et al., 2019). For severe Crohn’s disease, I use systemic steroids for induction and consider early anti-TNF or other biologics based on phenotype.

• Physiology: Corticosteroids suppress NF-κB and cytokine cascades; biologics target specific mediators to achieve mucosal healing and reduce complications.
• Rule out infection (especially difficile) before escalating immunosuppression.
• Monitor CRP daily and consider fecal calprotectin; use CT/MR enterography for complications.
• Thromboprophylaxis: IBD carries high VTE risk; I prefer short-half-life heparin and rarely see worsening rectal bleeding.

A hospital flare is a turning point for optimizing maintenance biologic therapy, checking antibodies against current agents, and adjusting dosing frequency.

Acute Pancreatitis: Fluids, Nutrition, and Pain Control

I favor aggressive early IV fluids—Lactated Ringer’s — to reduce systemic inflammation compared with saline (de-Madaria et al., 2022). Under-dosing fluids is common; I titrate to perfusion goals. I apply multimodal pain control:

• Scheduled NSAID (e.g., ketorolac if no contraindication, short duration)
• Scheduled acetaminophen
• Neuropathic agents (gabapentin/pregabalin) for sharp, stabbing pain
• Opioids for breakthrough only

I start early enteral nutrition — even clear high-protein drinks — to maintain gut integrity and reduce bacterial translocation; I avoid prophylactic antibiotics unless infection is confirmed. I differentiate early fluid collections (rarely drained) from mature pseudocysts (>4 weeks old with a thick wall) w, for which endoscopic drainage is considered if symptomatic.

Cholangitis vs. Choledocholithiasis: Infection vs. Obstruction

• Choledocholithiasis: CBD stone, cholestatic labs (alkaline phosphatase, GGT, bilirubin), dilated ducts on imaging.
• Acute cholangitis: Infection superimposed on obstruction; Charcot’s triad (fever, RUQ pain, jaundice) and Reynolds’ pentad (hypotension, AMS) suggest sepsis (Kiriyama et al., 2018).

Cholangitis requires urgent antibiotics and ERCP within 24 hours to decompress the biliary tree (Buxbaum et al., 2021). Obstruction alone may need ERCP but is less time-sensitive; I use MRCP/EUS if diagnosis is uncertain (ASGE Standards of Practice Committee, 2019).

Root Causes of *GUT DYSFUNCTION*- Video

Mesenteric Ischemia and Ischemic Colitis: Watershed Physiology

In systemic hypotension (e.g., during dialysis) with vascular disease, the colon’s watershed regions (splenic flexure and rectosigmoid) are vulnerable. CT may show bowel wall thickening in these zones; colonoscopy reveals dusky, friable mucosa or deep ulcers.

Management:

• Restore perfusion and blood pressure
• Consider anticoagulation and vascular evaluation if occlusion suspected
• Surgery for necrosis
• Gentle laxatives (e.g., polyethylene glycol) to maintain soft stool and minimize intraluminal pressure.

Fecal Impaction: Imaging-Guided, Hands-On Care

I pull up imaging to localize impaction:

• Right colon impaction: Oral laxatives to move stool; enemas are ineffective.
• Rectal impaction: Digital disimpaction first; otherwise, enemas and suppositories fail. I use lubricants and may pre-soften with glycerin suppositories.

Post-clearance, I start a new bowel regimen; overflow diarrhea is common and should not lead to withholding laxatives.

Restrictive Transfusion Strategy: Cirrhosis-Specific Adjustments

I transfuse at hemoglobin <7 g/dL in most GI bleed and at 7–8 g/dL in cardiovascular disease or symptomatic anemia (Villanueva et al., 2013). In cirrhosis with variceal bleeding, I target 7–8 g/dL, avoid excessive volume, and correct coagulopathy judiciously (Tripathi et al., 2015). Over-transfusion increases portal pressure and rebleeding.

Acute Liver Failure: Early Definition and NAC

I apply the following criteria: evidence of liver injury (elevated aminotransferases), INR ≥1.5, any encephalopathy, and onset within 26 weeks without preexisting cirrhosis (Lee, 2012). I act early: identify the etiology (e.g., acetaminophen toxicity), start N-acetylcysteine (NAC), manage the risk of cerebral edema and hypoglycemia, and refer early to transplant centers. NAC replenishes glutathione, limiting oxidative damage; I monitor for rare hypersensitivity.

Hepatic Encephalopathy: Precipitants and Treatment

Common precipitants:

• Infection (SBP, UTI, pneumonia)
• GI bleeding (nitrogen load)
• Electrolyte disturbances (hypokalemia, metabolic alkalosis)
• Constipation, sedatives, dehydration, renal dysfunction

Treatment:

• Lactulose titrated to 2–3 soft stools/day; I set hold parameters to avoid dehydration and electrolyte loss.
• Rifaximin to reduce ammonia-producing flora; prevents recurrence when added to lactulose (Bass et al., 2010).
• Nutrition: Adequate protein — I avoid overrestriction; plant and dairy proteins may produce less ammonia.

I counsel on driving safety due to cognitive effects; a local DMV assessment may be warranted.

Hepatorenal Syndrome (HRS): Pathophysiology and Therapy

Splanchnic vasodilation reduces effective arterial blood volume, triggering renal vasoconstriction and a decrease in GFR without structural damage. I use albumin to expand plasma volume and vasoconstrictors:

• Terlipressin (first-line where available); alternatives include norepinephrine in ICU or midodrine/octreotide combinations (Angeli et al., 2015).
• Address infections, hold nephrotoxins; consider TIPS and transplant

Ascites and Portal Hypertension Complications

I confirm portal hypertensive ascites with SAAG; I avoid fluid restriction unless sodium <120 mEq/L. I start morning diuretics (e.g., furosemide 40 mg plus spironolactone 100 mg) and titrate to minimize nocturia. For recurrent variceal bleeding, I perform serial banding and initiate non-selective beta-blockers; I favor carvedilol for its dual beta- and alpha-1-adrenergic effects, which reduce portal pressure and improve outcomes. For refractory cases, I consider early TI, PS ideally when MELD <18.

Portal Vein Thrombosis (PVT): When to Anticoagulate

I evaluate sudden decompensation (new ascites/encephalopathy) with Doppler ultrasound and CT/MRI to define extent and exclude malignant thrombus. Elevated INR does not protect against clotting. I generally avoid hypercoagulable workups in cirrhosis due to poor interpretability.

• Chronic occlusive PVT with cavernous transformation: focus on portal hypertension management and variceal screening; anticoagulation often not recommended.
• Acute PVT with ischemic symptoms: consider anticoagulation (DOACs selected on a case-by-case basis), sometimes without induction dosing to limit bleeding risk; follow with repeat imaging at 3–6 months (Northup et al., 2021).

Liver Enzymes vs. Liver Function: The Right Lens

• Liver injury markers, ALT and AST, reflect hepatocellular injury.
• Cholestatic markers: Alkaline phosphatase, GGT reflect bile duct involvement.
• Function indicators: Bilirubin, albumin, INR reflect excretory and synthetic function. True function is better captured by bilirubin and INR than aminotransferases.

I use the R-factor to classify injury patterns:

R = (ALT / ALT ULN) / (Alk Phos / Alk Phos ULN)

• R > 5: hepatocellular
• R < 2: cholestatic
• R 2–5: mixed

Aminotransferases in the thousands point to ischemic hepatitis, acute viral hepatitis, or severe DILI (e.g., acetaminophen). I reserve liver biopsy for diagnostic uncertainty or suspected autoimmune hepatitis with high-titer serologies.

I take meticulous histories, calling the pharmacist and explicitly asking about nonprescription supplements. I frequently see “liver cleanse” products cause DILI in patients told they have fatty liver.

Peptic Ulcer Disease: Root-Cause Strategy and Lifelong PPI in Select Patients

I ask: what truly caused the ulcer? NSAIDs, H. pylori, and pill esophagitis are common drivers.

• For NSAID-related ulcers, I switch to COX-2 selective agents and add PPI gastroprotection when high-risk. I emphasize non-NSAID pain plans — triptans when appropriate, magnesium, neuromodulators — and for osteoarthritis, structured exercise, weight management, topical NSAIDs, duloxetine, and targeted manual therapy.
• I test and treat pylori per ACG guidance and confirm eradication (Chey et al., 2017).
• For pill esophagitis, I counsel on upright dosing with water and avoiding recumbency for 30–60 minutes; I consider alternatives for high-risk patients.

In large hiatal hernias with CCameron’sulcers, I strongly advocate lifelong PPI when surgery is not feasible, especially if the patient requires long-term anticoagulation.

Integrative Chiropractic Care: Supporting GI and Liver Recovery

My integrative chiropractic and rehab methods complement medical therapy:

• Pain modulation without systemic NSAIDs: By improving joint mechanics, segmental mobility, and neuromuscular control, I reduce reliance on ulcerogenic medications — crucial post-bleed or in portal hypertension.
• Autonomic balance: Gentle, evidence-informed spinal manipulation and soft-tissue techniques can modulate sympathetic overactivity, influencing visceral pain and motility through visceral-somatic reflexes. Not a replacement for medical care, but a potent adjunct.
• Respiratory and rib mechanics: Optimized thoracic mobility supports diaphragmatic function, venous/lymphatic return, and reduces intra-abdominal pressure spikes that exacerbate reflux or portal pressures during strain.
• Graded exercise prescription: Enhances endothelial function, insulin sensitivity, and muscle mass, mitigating sarcopenia in cirrhosis and aiding NAFLD/MASLD
• Functional medicine support: Targeted nutrition, protein adequacy, fiber modulation, and microbiome-informed strategies complement lactulose/rifaximin regimens and support mucosal healing in IBD.

Under Dr. Cardenas’ oversight, we align manual therapy timing with anticoagulation and bleeding risks, monitor anemia and fluid-electrolyte status, and coordinate progression after ERCP or endoscopic therapy.

Clinical Observations and Practical Pathways

From complex radiculopathy to sciatica, patients often self-medicate with OTC NSAIDs they do not disclose unless specifically named. I emphasize explicit medication reconciliation and non-NSAID pain plans to reduce GI risk while preserving function (clinical notes at sciatica. clinic; LinkedIn: Dr. Alex Jimenez). In older adults, slow transit can mislead clinicians to an upper source when right-sided angiodysplasia is the culprit; early non-diagnostic after nondiagnostic EGD reduces length of stay and anesthesia exposure. For hepatic encephalopathy, caregiver engagement and lactulose titration education consistently lower readmissions; we integrate nutrition coaching to sustain outcomes.

Putting It All Together: A Practical Inpatient Pathway

• Initial assessment

• • Stabilize airway, breathing, circulation; check orthostatics.
  • Identify red flags for brisk upper GI bleeding.
  • Order CBC, CMP, INR, type and screen/crossmatch; consider BUN/Cr ratio.
  • Start high-dose IV PPI; add octreotide and antibiotics if varices suspected.

• Risk stratify and plan endoscopy

• • Use validated bleeding scores to guide level of care and timing.
  • Target EGD within 12–24 hours; consider early colonoscopy prep when colonic source suspected or EGD unlikely to explain severity.

• Medication and cause analysis

• • Conduct granular OTC and supplement review; test for pylori.
  • Adjust or reverse anticoagulation per agent and severity; plan resumption based on thrombotic risk and hemostasis.

• Hepatology-specific steps

• • Restrictive transfusion strategy (Hb 7–8 g/dL); avoid overcorrection in variceal bleeds.
  • Screen and treat precipitating factors for hepatic encephalopathy; lactulose plus rifaximin when indicated.
  • Evaluate for HRS if renal function declines in advanced liver disease; initiate albumin and appropriate vasoconstrictors.
  • Consider acute liver failure criteria; start NAC when indicated and refer early to transplant-capable centers.

• Integrative overlay

• • Implement non-NSAID pain strategies, targeted manual therapy, and graded exercise.
  • Provide nutrition support for mucosal healing and protein adequacy.
  • Coordinate close outpatient follow-up under  Cardenas’oversight to align medical and chiropractic care.

This comprehensive, integrative model shortens recovery timelines, reduces avoidable readmissions, and delivers practical strategies that fit real-world needs.

References

• ASGE Standards of Practice Committee. The role of endoscopy in the evaluation and management of dysphagia. Gastrointestinal Endoscopy, 79(2), 191–201 (2014).
• ASGE Standards of Practice Committee. Role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointestinal Endoscopy, 89(6), 1075–1105 (2019).
• Angeli, P., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 62(4), 968–974 (2015).
• Barkun, A. N., et al. Management of nonvariceal upper gastrointestinal bleeding: Guideline recommendations. Annals of Internal Medicine, 171(11), 805–822 (2019).
• Bass, N. M., et al. Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine, 362(12), 1071–1081 (2010).
• Buxbaum, J. L., et al. ASGE guideline on the role of endoscopy in the management of choledocholithiasis. Gastrointestinal Endoscopy, 93(5), 1085–1100.e12 (2021).
• Chavez-Tapia, N. C., et al. Antibiotic prophylaxis for cirrhotic patients with upper GI bleeding. Cochrane Database of Systematic Reviews, (9): CD 002907 (2013).
• Chey, W. D., et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology, 112(2), 212–239 (2017).
• de-Madaria, E., et al. Aggressive or moderate fluid resuscitation in acute pancreatitis. New England Journal of Medicine, 387(11), 989–1000 (2022).
• Kiriyama, S., et al. Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences, 25(1), 17–30 (2018).
• Laine, L., & Jensen, D. M. Management of patients with ulcer bleeding. American Journal of Gastroenterology, 107(3), 345–360 (2012).
• Lee, W. M. Acute liver failure. New England Journal of Medicine, 367(24), 2329–2339 (2012).
• Northup, P. G., et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by AASLD. Hepatology, 73(1), 366–413 (2021).
• Qureshi, W., et al. Restarting anticoagulation after GI bleeding reduces thromboembolism and mortality. Journal of the American College of Cardiology, 63(16), 1630–1636 (2014).
• Rubin, D. T., et al. ACG clinical guideline: Ulcerative colitis in adults. American Journal of Gastroenterology, 114(3), 384–413 (2019).
• Tripathi, D., et al. UK guidelines on the management of variceal hemorrhage in cirrhotic patients. Gut, 64(11), 1680–1704 (2015).
• Villanueva, C., et al. Transfusion strategies for acute upper GI bleeding. New England Journal of Medicine, 368(1), 11–21 (2013).

Author and Clinical Insights

• Clinical insights and patient education: https://sciatica.clinic/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

SEO tags: upper GI bleeding, melena vs hematochezia, proton pump inhibitor therapy, octreotide variceal bleeding, choledocholithiasis vs cholangitis, urgent ERCP timing, dysphagia workup, oropharyngeal vs esophageal dysphagia, ulcerative colitis severe flare, CCrohn’sdisease inpatient steroids, anticoagulation reversal GI bleed, restrictive transfusion strategy, cirrhosis transfusion threshold, acute liver failure criteria, hepatic encephalopathy lactulose rifaximin, hepatorenal syndrome albumin vasoconstrictors, liver enzymes vs liver function, integrative chiropractic care GI, functional medicine gastroenterology, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, Cameron’s ulcers, Watchman procedure, mesenteric ischemia watershed, fecal impaction disimpaction, acute pancreatitis lactated Ringer’s, carvedilol portal hypertension, TIPS procedure, portal vein thrombosis